Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05625659 · ClinicalTrials.gov registry record · NA

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

A NA study of Breast Cancer, sponsored by American College of Radiology.

Recruiting
Registry status
NA
Development phase
2,032
Enrollment target
11
Study locations

NCT05625659: Recruiting NA study of Breast Cancer, sponsored by American College of Radiology.

NCT05625659 is a NA study of Breast Cancer that is actively recruiting participants, run by American College of Radiology. The registered enrollment target is 2,032 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (27% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05625659, a NA study of Breast Cancer, is actively recruiting participants, sponsored by American College of Radiology.

RECRUITING
Registry status
NA
Development phase
2,032 participants
Enrollment target
11
Study locations

Study Summary

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.

Primary Outcome

The cancer detection rate (CDR) at the participant level at Year 0. This measure will be evaluated for CESM and DBT

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)

Study Locations (11)

Florida

  • Boca Raton Regional Hospital - Christine E. Lynn Women's Health and Wellness Institute - Boca Raton
  • Lake Medical Imaging - The Villages

Alabama

  • University of Alabama, Birmingham - Birmingham

Massachusetts

  • Boston Breast Diagnostic Center - Wellesley Hills

Michigan

  • Henry Ford Health - Detroit

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Carolina Breast Imaging Specialists - Greenville

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 2,032 participants
Start Date 2023-03-24
Est. Completion 2027-07-31
Phase NA
American College of Radiology

14 total trials

What NCT05625659 shows while recruiting

NCT05625659 is an interventional study that assigns participants to a tested intervention. Its 2,032 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (27% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) is the first listed.

NCT05625659 lists 11 locations in 10 states (Florida, Alabama, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT05625659 about?

NCT05625659 is a clinical study titled "Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts". The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai...

What is the current status of trial NCT05625659?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,032 participants. The study started on 2023-03-24. Estimated completion is 2027-07-31.

What conditions does trial NCT05625659 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05625659?

The interventions under investigation include: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05625659?

This trial is sponsored by American College of Radiology, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05625659 being conducted?

This trial has 11 study locations across Alabama, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05625659's enrollment target sits among peer trials

2,032 68th of 1224 higher than 1,157 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04216732 · 2,030 participants

    Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

  • NCT06825897 · 2,039 participants · NA

    Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

  • NCT05138718 · 2,041 participants

    FDG an Myocardial Infarction: The PIAF Trial

  • NCT06833476 · 2,044 participants

    TTVR STRONG Under Coverage With Evidence Development (CED) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05625659, the US trial registry maintained by the National Library of Medicine. NCT05625659 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.